Available online 23 June 2017 Purinergic signaling, mediated mainly by G protein-coupled P2Y receptors (P2YRs), is now attracting attention as a new therapeutic target for preventing or treating cardiovascular diseases. Observations using mice with genetically modified P2YRs and/or treated with a pharmacological P2YR inhibitor have helped us understand the physiological and pathological significance of P2YRs in the cardiovascular system. P2YR-mediated biological functions are predominantly activated by mononucleotides released from non-adrenergic, non-cholinergic nerve endings or non-secretory tissues in response to physical stress or cell injury, though recent studies have suggested the occurrence of ligand-independent P2YR function through receptor-receptor interactions (oligomerization) in several biological processes. In this review, we introduce the functions of P2YRs and possible dimerization with G protein-coupled receptors (GPCRs) in the cardiovascular system. We focus especially on the crosstalk between uridine nucleotide-responsive P2Y 6 R and angiotensin (Ang) II type1 receptor (AT1R) signaling, and introduce our recent finding that the P2Y 6 R antagonist MRS2578 interrupts heterodimerization between P2Y 6 R and AT1R, thereby reducing the risk of AT1R-stimulated hypertension in mice. These results strongly suggest that targeting P2Y 6 R oligomerization could be an effective new strategy to reduce the risk of cardiovascular diseases.
Introduction
Adenosine 5′-trisphosphate (ATP), a common energy currency used in all biological cells, also acts as an important extracellular signaling molecule. ATP and other purine and pyrimidine nucleotides are released from non-adrenergic, non-cholinergic nerve endings as well as from non-secretory tissues in response to stresses such as cell injury. The released nucleotides then modulate cellular functions through the activation of membrane-bound purinergic receptors. The term "purinergic" was introduced in 1972 by Burnstock (1972) , who then classified purinergic receptors based on their ligand specificity (Burnstock, 2012) . In addition to mononucleotides, dinucleotide phosphates, such as uridine adenosine tetraphosphate (Up4A) and diadenosine polyphosphate (ApnA) released from various cells including neuronal and endothelial cells (Durnin et al., 2014) , also participate in purinergic receptor-mediated biological functions, including platelet aggregation and vasoregulation (Wiedon et al., 2012) . The many purinergic receptors so far identified have been divided into several subtypes based on their molecular structures, pharmacological characteristics and signal transduction mechanisms (Abbracchio & Burnstock, 1994; Burnstock & Kennedy, 1985) . There are two major families of purinergic receptors: P1 receptors for adenosine and P2 receptors for ATP. P1 receptors are G protein-coupled receptors (GPCRs) subdivided into A 1 , A 2A , A 2B and A 3 receptors. P2 receptors are subclassified into ion channel-type P2XRs and GPCR-type P2YRs. To date, seven P2XRs (P2X1-7R) and eight P2YRs (P2Y 1 R, P2Y 2 R, P2Y 4 R, P2Y 6 R, P2Y 11 R, P2Y 12 R, P2Y 13 R and P2Y 14 R) have been identified in mammals. To activate these purinergic receptors, nucleotides are released from cells to extracellular space via several mechanisms (Lazarowski, Boucher, & Harden, 2003) (Fig. 1) . (I) ATP is co-packaged with other molecules into vesicle and released by exocytosis in excitatory cells as well as non-excitatory cells such as endothelial and chromaffin cells. Vesicular ATP transport proteins such as VNUT and SLC17A9 are identified (Larsson et al., 2012; Sawada et al., 2008) . (II) ATP is released through ATP-permeable channels, such as ATP-binding cassette transporters (Lazarowski et al., 2003) , P2X7R (Lazarowski et al., 2003) , connexin (Schock, LeBlanc, Hakim, & Thompson, 2008) and pannexin (Dahl, 2015; Nishida et al., 2008) . (III) Under pathological conditions, nucleotides with other cytosolic compartments are leaked from damaged cells.
Purinergic signaling plays pivotal roles in a wide range of physiological and pathophysiological processes in vertebrates, including neurotransmission, cardiovascular function, postnatal development and aging (Burnstock, 2006; Burnstock & Dale, 2015; Erlinge & Burnstock, 2008) . Indeed, recent studies using purinergic receptor-knockout mice have revealed the biochemical and functional diversity of purinergic receptors in various organs (Boeynaems, Communi, Gonzalez, & Robaye, 2005; Dubyak, 2003; Sunggip et al., 2017) . Structural analyses have also shown that two different adenosine 5′-diphosphate (ADP)-sensitive P2YRs (P2Y 1 R and P2Y 12 R) interact with their nucleotide ligands in different binding modes (Zhang, Zhang, Gao, Paoletta, et al., 2014; Zhang, Zhang, Gao, Zhang, et al., 2014; Zhang et al., 2015) , which broadens further the diversity of signal recognition mechanisms in P2YRs. Additionally, several P2YRs form homo-or heterodimers, thereby amplifying and/or modifying downstream signaling pathways to induce various cellular functions (Erb & Weisman, 2012) . In this review, we introduce the diverse functions of P2YRs in the cardiovascular system and the importance of P2YR dimerization in several pathological processes, including platelet aggregation (P2Y 12 R homodimerization) (Savi et al., 2006) and age-dependent hypertension (AT1R-P2Y 6 R hetero-dimerization) (Nishimura et al., 2016) . These findings raise the possibility that P2Y 6 R could be an effective new target for the prevention and treatment of cardiovascular diseases.
Biochemical properties of P2YRs
All P2YR subtypes contain the typical GPCR features, including seven predicted hydrophobic transmembrane regions connected by three extracellular loops (EL-1 to EL-3) and three intracellular loops (IL-1 to IL-3). The molecular weights of the glycosylated P2YR proteins range from 41 (P2Y 6 R) to 53 (P2Y 4 R) kDa, as predicted by the amino acid sequences. The crystal structures of P2Y 1 R and P2Y 12 R were recently solved and revealed the structural basis for their ligand action (Zhang, Zhang, Gao, Paoletta, et al., 2014; Zhang, Zhang, Gao, Zhang, et al., 2014; Zhang et al., 2015) . The molecular diversity is central to their ligand selectivity, post-translational modification, specificity of coupling to heterotrimeric G proteins, and interaction with other signaling proteins, including GPCRs and integrins.
Ligand selectivity
P2XRs are selectively activated by ATP, while P2YRs are activated by ATP and other naturally occurring nucleoside phosphates (Fig. 2) . ATP is the primary physiological P2Y 11 R agonist (Morrow, Nicholas, & Kennedy, 2014) . P2Y 2 R and P2Y 4 R are also activated by ATP as well as UTP. Other P2YRs are less responsive to ATP. ADP is the native agonist for P2Y 1 R, P2Y 12 R and P2Y 13 R. P2Y 6 R and P2Y 14 R are activated by UDP and UDP-glucose, respectively. Some nucleotides activate one receptor and antagonize another. ATP and UDP act as antagonists at P2Y 12 R and (in humans but not rats) P2Y 14 R, respectively (Fricks et al., 2008; Kauffenstein, Hechler, Cazenave, & Gachet, 2004) . Dinucleoside polyphosphates also act as potent and selective agonists at P2YRs. For example, Up4A promotes vascular smooth cell migration through P2Y 2 R activation (Wiedon et al., 2012) . In addition to these native ligands, numerous synthetic P2YR agonists and antagonists have been developed. The structural and pharmacological properties of these synthetic ligands are well summarized in other reviews (Jacobson, Ivanov, de Castro, Harden, & Ko, 2009; Jacobson, Jayasekara, & Costanzi, 2012; von Kügelgen & Hoffmann, 2016) . The crystal structures of P2YR with bound ligands reveals the varied receptor-binding properties of these synthetic ligands (Zhang, Zhang, Gao, Paoletta, et al., 2014; Zhang, Zhang, Gao, Zhang, et al., 2014; Zhang et al., 2015) . 
Post-translational modification
The P2YRs expressed on the plasma membrane are modified by Nlinked glycosylation (Erb, Lustig, Sullivan, Turner, & Weisman, 1993; Zhong, Kriz, Seehra, & Kumar, 2004) . For example, N-linked glycosylation is required for P2Y 12 R-mediated signal transduction, but not for ADP binding or cell surface expression (Zhong et al., 2004) . N-glycosylation is required for the plasma membrane localization of P2Y 2 R, and Nglycosylation-deficient P2Y 2 R mutant is accumulated in lipid raft in ER (Nakagawa et al., 2017) . All P2YR subtypes possess four cysteine residues at the extracellular side, which likely to form two disulfide bonds, coupling the N-terminus to EL-3 and helix III to EL-2 (Hoffmann, Moro, Nicholas, Harden, & Jacobson, 1999) . Both of these disulfide bridges are observed in the agonist-bound structure of P2Y 12 R (Zhang, Zhang, Gao, Paoletta, et al., 2014) and antagonist-bound structure of P2Y 1 R (D. Zhang et al., 2015) . Cysteine-to-alanine mutation disrupting the N-terminus-to-EL-3 disulfide bridge leads to receptor aggregation, suggesting this bridge is required for overall structural integrity (Zhang, Zhang, Gao, Zhang, et al., 2014) . On the other hand, the cysteine residues forming the helix III-to-EL-2 bridge are directly involved in agonist binding, and substituting these cysteines alters agonist affinity (Zhang, Zhang, Gao, Paoletta, et al., 2014) . Interestingly, the helix III-to-EL-2 bridge is not resolved in antagonist-bound P2Y 12 R (Zhang, Zhang, Gao, Zhang, et al., 2014) . The active metabolites of prasugrel and clopidogrel, which contain a reactive thiol group interact with these cysteine residues for P2Y 12 R inhibition (Algaier, Jakubowski, Asai, & Von Kugelgen, 2008; Ding, Bynagari, Mada, Jakubowski, & Kunapuli, 2009) (Fig. 3) . Functional P2Y 12 Rs form lipid raft-associated homo-oligomeric complexes on the surface of mammalian cells, and the active clopidogrel metabolite induces breakdown of these oligomers into dimeric and monomeric entities (Savi et al., 2006) . Other thiol-reactive reagents such as p-chloromercuribenzene sulphonate (pCMBS) also inhibit P2Y 12 R (Ohlmann et al., 2013) . These findings suggest the function of P2YRs is redox sensitive, and that post-translational modification of P2YRs is essential for ligand affinity and functional maturation of P2YRs.
G protein coupling
All P2YRs couple with heterotrimeric G proteins, consisting of an α subunit (Gα) tightly associated with βγ subunits (Gβγ) at the inner surface of the plasma membrane. Heterotrimeric G proteins have been broadly divided into four subfamilies (G q , G s , G i/o , and G 12/13 ), each activating different downstream effectors. G s and G i respectively stimulate and suppress adenylyl cyclase activity. G q activates PLCβ, while G 12/13 couples with RhoGEF. The combination of specific P2YR and G protein subtypes is thought to define the specificity of the resultant P2YR signaling.
P2YRs have been grouped into two subfamilies based on their sequence similarity and G protein selectivity: P2Y 1 -like receptors (P2Y 1 R, P2Y 2 R, P2Y 4 R, P2Y 6 R, and P2Y 11 R) share 28-52 % sequence homology and couple mainly with G q , while P2Y 12 -like receptors (P2Y 12 R, P2Y 13 R, and P2Y 14 R) share 45-50% sequence homology and couple mainly with pertussis toxin-sensitive G i/o (Erb & Weisman, 2012) . Most G q -coupled receptors are known to couple with other G protein subfamilies, especially G i/o and G 12/13 , while P2Y 11 R is able to couple with G s (Fig. 2) . G s -mediated P2Y 11 R signaling is important for such physiological events as neutrophil apoptosis and monocyte migration (Kaufmann et al., 2005; Nguyen, Meichle, Kim, Wong, & Moody, 2001; Vaughan et al., 2007). Flock et. al. recently revealed the molecular mechanism of selective GPCR-G protein coupling. Distinct regions on GPCRs can recognize the selectivity barcode (that is patterns of amino acids) on each G proteins (Flock et al., 2017) . We previously reported that P2Y 6 R couples with G 12/13 and participates in pressure overload-induced cardiac remodeling, especially interstitial fibrosis, through RhoAdependent signaling pathways (Nishida et al., 2008) . This mechanism of stretch-induced cardiac fibrosis involves the release of ATP and UDP from cardiomyocytes through pannexin-1 channels, which mediate autocrine and paracrine activation of P2Y 6 R in cardiomyocytes.
β-arrestin-dependent internalization and signaling
Ligand-stimulated activation of GPCRs often initiates receptor desensitization and internalization. Ligand-dependent GPCR desensitization is generally initiated by phosphorylation of Ser/Thr residues in the intracellular domain of GPCRs by a family of GPCR kinases (GRK1-7). The Ser/Thr-phosphorylated GPCR is targeted by β-arrestins (β-Arr1-4), which promote desensitization and endocytosis of the receptor. Adaptor protein-2 then binds to the P2YR-β-Arr complex. This is The disulfide bridge between helix III and EL-2 was absent in the crystal structure of antagonist-bound P2Y 12 R. Clopidogrel is metabolically converted into an active metabolite containing a reactive thiol group. This thiol group enables the active metabolite to directly bind to the cysteine residue in helix III and inhibit receptor activity.
often required for recycling GPCRs, including P2YRs (Wagener, Marjon, Revankar, & Prossnitz, 2009 ). In addition to receptor internalization, β-Arr mediates G protein-independent P2YR signaling through interaction with mitogen-activated protein kinases (MAPKs) and Src tyrosine kinase. For instance, P2Y 12 R regulates microglia chemotaxis via a β-Arr2-dependent ERK signaling pathway (Lee, Hollingsworth, Kwon, Lee, & Chung, 2012) . It appears that all P2YRs interact with β-Arr in response to extracellular nucleotide, but the kinetics and components of P2YR internalization differ among the receptor subtypes. All P2YR subtypes interact to some degree with β-Arr2, whereas P2Y 2 R and P2Y 4 R interact with both β-Arr1 and β-Arr2 (Hoffmann, Ziegler, Reiner, Krasel, & Lohse, 2008) . Interestingly, P2Y 2 R is activated equally by ATP or UTP (Erb et al., 1993) , but while stimulation by ATP induces strong interaction with β-Arr1 and weak interaction with β-Arr2, stimulation by UTP induces a strong interaction with both β-Arr1 and β-Arr2 (Hoffmann et al., 2008) . This differential coupling may create a diverse spatiotemporal activation profile for P2Y 2 R-mediated, β-Arr-dependent MAPK signaling. Na + /H + exchanger regulatory factor (NHERF)-1 and -2 that are PDZ motif-binding proteins interact with C-terminal tail of P2Y 12 R and P2Y 1 R and regulate their internalization (Fam et al., 2005; Nisar et al., 2012) . Small GTP-binding protein ADP ribosylation factor 6 (Arf6) which is important for platelet function (W. Choi, Karim, & Whiteheart, 2006; Karim, Choi, & Whiteheart, 2008 ) also regulate dynamin-dependent internalization of P2Y 1 R and P2Y 12 R in human platelets (Kanamarlapudi, Owens, Saha, Pope, & Mundell, 2012) . In addition, internalization of P2Y 2 R, but not other P2YRs, is not inhibited by a dominant negative form of dynamin, which suggests internalization of P2Y 2 R is dynamin independent (Hoffmann et al., 2008) . Uridine nucleotide-activated P2Y 4 R and P2Y 6 R show different internalization kinetics. P2Y 4 R is rapidly desensitized after UTP stimulation, whereas P2Y 6 R internalization is very slow. C-terminal serine residues in P2Y 4 R, which are not conserved in P2Y 6 R, are phosphorylated in response to UTP and are indispensable for the receptor's rapid internalization (Brinson & Harden, 2001 ). The recycling machinery for the ADP receptors P2Y 1 R and P2Y 12 R also distinctly differ. Internalization of P2Y 12 R is dependent on the activities of GRK2 and GRK6, while P2Y 1 R internalization is PKC-dependent (Hardy et al., 2005) . After internalization, P2Y 12 R is rapidly recycled back to the plasma membrane via a Rab4/11-dependent trafficking pathway (Cunningham, Nisar, & Mundell, 2013) , while P2Y 1 R is slowly recycled by Sorting Nexin 1 (Nisar, Kelly, Cullen, & Mundell, 2010) .
Interaction with extracellular matrix proteins
A three-amino acid RGD (Arg-Gly-Asp) motif is originally identified in fibronectin and binds to integrin. Both mouse P2Y 2 R and P2Y 6 R possess the RGD motif in their EL-1 region. In contrast to human and mice P2Y 2 R, rat P2Y 2 R possesses QGD sequence instead of RGD. However the change of RGD to QGD is considered to maintain integrin binding ability (Erb et al., 2001; Gresham, Adams, & Brown, 1992) . The RGD motif is also observed in several adhesion GPCRs, including BAI1, ADGRA2 and GPR124, and is recognized by integrin. The interaction of α v integrin with P2Y 2 R through its RGD domain is reportedly required for G o -and G 12 -coupling but not G q -coupling (Bagchi et al., 2005; Erb et al., 2001; Liao, Seye, Weisman, & Erb, 2007) . The P2Y 2 R RGD motif is important for shear stress-induced migration of human umbilical vein endothelial cells (Sathanoori et al., 2017) and tubule formation by epithelial IEC6 cells (Ibuka, Matsumoto, Fujii, & Kikuchi, 2015) .
Oligomerization of P2YRs
Although biochemistry-based studies have shown that monomeric GPCRs are functional (Ernst, Gramse, Kolbe, Hofmann, & Heck, 2007; Whorton et al., 2007) , some GPCRs exist as homo-or hetero-oligomers (Ernst et al., 2007) . P2Y 1 R, P2Y 4 R, P2Y 6 R, P2Y 12 R and P2Y 13 R all form homo-oligomers within cells (Choi, Simon, Tsim, & Barnard, 2008; D'Ambrosi et al., 2006; D'Ambrosi, Iafrate, Saba, Rosa, & Volonté, 2007; Savi et al., 2006) (Table 1) . Crystal structure of antagonist-bound P2Y 12 R shows that receptor forms homodimer through helix V and two cholesterol molecules (Zhang, Zhang, Gao, Zhang, et al., 2014) . Ligand binding alters oligomeric state of P2YRs. Agonist stimulation promotes oligomer formation by P2Y 1 R and P2Y 6 R, and the P2Y 12 R Table 1 Oligomerization of P2YRs and their functions.
Homo-oligomerization Receptor Detection
Characteristics and functions Ref inhibitor clopidogrel disrupts the oligomer formation Savi et al., 2006) . P2YR homo-oligomerization regulates its lipid raft localization. P2Y 12 R oligomer localizes at lipid raft and clopidogrel-treated monomeric form elicits it partition out of lipid raft (Savi et al., 2006) . P2Y 4 R monomer also exists only in non-raft fraction, whereas P2Y 6 R localizes at lipid raft as monomeric form (D'Ambrosi et al., 2007) . Ligandbound P2Y 1 R and P2Y 2 R transmit signal in lipid raft, and then receptors are dissociated from lipid raft and internalized (Martinez et al., 2016; Norambuena et al., 2008) . P2Y 2 R associates with caveolin-1 for lipid raft localization and downstream signaling machinery (Martinez et al., 2016) . These evidences suggest homo-oligomerization is related with P2YR activity and localization. P2Y 1 R heterodimerizes with P2Y 11 R. P2Y 11 R is itself not able to undergo agonist-induced internalization, but P2Y 1 R-P2Y 11 R heterodimerization promotes internalization (Ecke et al., 2008) . Both P2Y 1 R and P2Y 2 R form hetero-oligomers with adenosine A 1 R. Within the P2Y 1 R-A 1 R complex, the P2Y 1 R agonist directly binds to the A 1 R binding pocket and transmits a G i -mediated signal through A 1 R activation (Nakata, Yoshioka, Kamiya, Tsuga, & Oyanagi, 2005; Yoshioka, Saitoh, & Nakata, 2001) , while simultaneous activation of P2Y 2 R and A 1 R reduces A 1 R-G i signaling but promotes P2Y 2 R-G q signaling (Suzuki, Namba, Tsuga, & Nakata, 2006) .
P2YRs form hetero-oligomers with purinergic GPCRs as well as other types of GPCRs. We recently reported heterodimer formation by P2Y 6 R with the angiotensin (Ang) II type-1 receptor (AT1R) (Nishimura et al., 2016) . Formation of this heterodimer inhibits β-Arr recruitment to AT1R after Ang II treatment, which diminishes β-Arr-dependent signaling and enhances G protein-dependent signaling. P2Y 6 R expression is developmentally increased in vascular smooth muscle cells, and AT1R-mediated G protein-dependent signaling is predominant in adult cells. Because UDP has no impact on the heterodimer formation, P2Y 6 R is suggested to regulate AT1R signaling in nucleotide ligand-independent manner. In addition, P2Y 12 R forms a heterodimer with protease activated receptor (PAR) 4, but not PAR1, which regulates β-Arr-mediated Akt signaling (Khan, Li, Ibrahim, Smyth, & Woulfe, 2014) . These findings indicate that receptor oligomerization generates diverse purinergic signaling by altering receptor characteristics such as ligand selectivity and G protein and β-Arr coupling.
Role of P2YRs in vascular homeostasis and disease

Vascular tone regulation
Arteries and veins are composed of three layers: the intima, media and adventitia. The intima is composed of a single layer of endothelial cells. The media is a contractile and elastic layer composed mainly of vascular smooth muscle cells. And the adventitia is primarily composed of fibroblasts and perivascular nerves embedded in collagenous tissue. The contractile state of the media determines the vascular tone, which is important for control of blood pressure. Purinergic signals regulate vascular tone through nucleotide release from both perivascular nerves and endothelial cells.
Perivascular sympathetic nerves release ATP as a co-transmitter with noradrenaline. The ATP mainly activates P2X1Rs on vascular smooth muscle cells inducing vasoconstriction (Vial & Evans, 2002) . Likewise, P2Y 12 Rs also mediate ATP and ADP-induced vasoconstriction in rat and human arteries (Mitchell, Syed, Tengah, Gurney, & Kennedy, 2012; Wihlborg et al., 2004) (Table 2) .
On the other hand, endothelial cells trigger vasodilation through blood flow-induced nucleotide release (Burnstock, 2009 ). Blood flow induces ATP release from endothelial cells by activating PIEZO1 mechanosensitive cation channels (Wang et al., 2016) . The hemichannel pannexin1/2 also participates in flow-induced ATP release. It has been suggested that inotropic P2X4R contribute to fluid flow-dependent vasodilation by mediating ATP-induced Ca 2+ influx into endothelial cells (Yamamoto et al., 2000 (Yamamoto et al., , 2006 . However, it remains unclear whether the elevated blood pressure and defective adaptive vascular remodeling seen in global P2X4R-deficient mice can be attributed to the loss of P2X4R from endothelial cells or from other cells (Yamamoto et al., 2006) . Human vascular endothelial cells contain G q -coupled P2Y 1 Rs, P2Y 2 Rs and P2Y 6 Rs (Wang et al., 2002) . Recent in vitro studies indicate that fluid sheer stress-induced nitric oxide (NO) production involves P2Y 2 Rs rather than P2XRs (Raqeeb, Sheng, Ao, & Braun, 2011; Wang et al., 2015) . Using human and bovine aortic endothelial cells, Wang et al. demonstrated sheer stress-induced endothelial responses, including transient increases in the intracellular Ca 2+ concentration, activation of the endothelial NO synthase (eNOS), phosphorylation of PECAM-1 and VEGFR-2, and activation of Src and Akt. Mice with an endothelium-specific P2Y 2 R or G q/11 deficiency lacked flow-induced vasodilation and exhibited a hypertensive phenotype that was accompanied by reduced eNOS activity. In addition to eNOS, prostaglandins and endothelium-derived hyperpolarizing factor (EDHF) are also involved in nucleotide-induced vasodilation in human arteries (Wihlborg et al., 2003) . A study of P2Y 6 R knockout mice revealed the central role of P2Y 6 Rs in determination of arterial myogenic tone (Kauffenstein et al., 2016) . Increases in pressure induce myogenic tone in the mesenteric artery, and that response is dramatically impaired by pharmacological inhibition and P2Y 6 R gene knockout. Chronic heart failure leads to increased peripheral vascular resistance resulting from enhanced myogenic tone (Gschwend et al., 2003) . Notably, P2Y 6 R-deficiency reduces chronic heart failure-induced increases in myogenic tone. This likely reflects the fact that pressure induces UDP release, probably through the hemichannel Cx43 and P2X7R, after which UDP acts in an autocrine or paracrine manner via P2Y 6 R to induce vasoconstriction. In these cells, P2Y 6 R induces G q/11 -mediated increases in intracellular Ca 2+ and G 12/13 -mediated RhoA activation, both of which affect vascular contraction by modulating phosphorylation of myosin light chain.
3.2. Atherosclerosis 3.2.1. Vascular wall remodeling through purinergic signaling Atherosclerosis is a major cause of mortality and morbidity in western countries. Studies in knockout mice revealed the involvement of P2Y 1 R, P2Y 2 R, P2Y 6 R, P2Y 12 R and P2Y 13 R in atherosclerosis (Chen et al., 2017; Garcia et al., 2014; Hechler et al., 2008; Lichtenstein et al., 2015; Qian et al., 2016; Stachon et al., 2014 Stachon et al., , 2016 West, Steiner, Judge, Francis, & Storey, 2014; Zerr et al., 2011) . In particular, endothelial specific P2Y 2 R deletion prevents atherosclerosis in apolipoprotein E null (ApoE −/− ) mice (Chen et al., 2017) . Vascular injury is a critical initiating event for atherosclerosis. Extracellular nucleotides released from injured cells and acting on vascular smooth muscle and endothelial cells mediate vascular remodeling leading to development of atherosclerotic lesions.
Vascular remodeling refers to structural changes in the vascular wall that involve changes in several cellular processes including proliferation, migration, cell death and modification of the extracellular matrix. ADP promotes proliferation of cultured endothelial cells through P2Y 1 R and P2Y 13 R (Lyubchenko et al., 2011; McAuslan, Reilly, Hannan, & Gole, 1983) . ATP and UTP promote phosphatidylinositol 3-kinase (PI3K)-dependent migration of human umbilical vein endothelial cells (Kaczmarek et al., 2005) , probably via P2Y 2 Rs and P2Y 4 Rs, whereas P2Y 11 R-mediated cAMP signaling inhibits endothelial cell migration (Avanzato et al., 2016 ). An early study showed that ATP and ADP stimulate DNA synthesis and proliferation in cultured vascular smooth muscle cells (Wang, Huang, & Heppel, 1992) . UDP and UTP also act as powerful mitogenic factors in vascular smooth muscle cells (Erlinge, You, Wahlestedt, & Edvinsson, 1995; Hou et al., 2002; Malam-Souley et al., 1996) , suggesting P2Y 1 R, P2Y 2 R, P2Y 4 R and P2Y 6 R all mediate proliferative signaling in these cells. Both ERK and PI3K signaling pathways are required for ATP-mediated vascular smooth muscle cell proliferation (Wilden, Agazie, Kaufman, & Halenda, 1998). Moreover, mitogenic effects mediated via P2YR are synergistic with effects of other growth factors, including PDGF, EGF, TGF-β, insulin and insulin-like growth factor (Crowley, Dempsey, Horwitz, & Horwitz, 1994; Wang et al., 1992) . ADP, ATP, UDP and UTP also promote migration of rat vascular smooth muscle cells (Chaulet et al., 2001) . P2Y 2 R binds to the actin-binding protein filamin A, which is involved in UTP-induced actin reorganization and cell migration (Yu, Erb, Shivaji, Weisman, & Seye, 2008) .
Inflammatory responses mediated by purinergic signaling
Inflammation also plays a central role in atherosclerosis. Infiltration of blood-derived leukocytes, monocytes and macrophages into the earliest lesions drives the development of atherosclerotic plaques (Libby, Ridker, & Maseri, 2002) . Normal endothelium does not support the binding and invasion of leukocytes. When the endothelium becomes inflamed, however, endothelial cells express adhesion molecules such as vascular cell adhesion molecule-1 (VCAM-1), intercellular adhesion molecule-1 (ICAM-1) and P-selectin on their surface, which support the binding and invasion of inflammatory cells. Early studies showed that extracellular nucleotides such as ATP and UTP regulate leukocyte adherence to endothelial cells (Parker, Likar, Dawicki, & Rounds, 1996) , and that P2Y 2 R activation triggers VCAM-1 expression (Seye et al., 2003) . Endothelial P2Y 2 R signaling mediates macrophage invasion through VCAM-1 upregulation, inhibition of smooth muscle cell migration, and activation of matrix metalloproteinase-2, causing atherosclerotic plaque instability. Bone-marrow transplantation assays also revealed the importance of non-hematopoietic derived P2Y 1 R, P2Y 6 R and P2Y 12 R in atherosclerosis (Hechler et al., 2008; Stachon et al., 2014; West et al., 2014; Zerr et al., 2011) . P2Y 6 R expression in endothelial cells is markedly upregulated after inflammatory stimulation, and P2Y 6 R inhibition significantly reduces TNF-α-induced VCAM-1 expression (Riegel et al., 2011) (Fig. 4) . In macrophages, P2Y 6 R promotes secretion of pro-inflammatory cytokines, which are also involved in atherosclerotic lesion development in high fat-fed low density lipoprotein receptor null (LDLR ApoE, apolipoprotein E; ECs, endothelial cells; TNFα, tumor necrosis factor α; VSMCs, vascular smooth muscle cells; FLNa, filamin A; LTα, lymphotoxin α; MLC, myosin light chain; LDLR, low density lipoprotein receptor; LPS, lipopolysaccharide; Mϕ, macrophages; NO, nitric oxide; NF-κB, nuclear factor-κB.
Although P2Y 1 R, P2Y 2 R, P2Y 6 R and P2Y 12 R deficiencies exert protective effects against atherosclerotic lesion development, P2Y 13 R deficiency exacerbates atherosclerosis in mice (Lichtenstein et al., 2015) . Bonemarrow transplantation assays showed that non-hematopoietic-derived P2Y 13 R protects against atherosclerosis development by mediating hepatobiliary reverse cholesterol transport.
Thrombosis
Arterial thrombosis is a condition in which platelets form a blood clot within vessels and is a major factor contributing to myocardial infarctions and strokes. Extracellular nucleotides, especially ADP, are closely related to the development of thrombosis through their key roles in platelet activation. Within platelets, two ADP receptors, P2Y 1 R and P2Y 12 R, and one ATP receptor, P2X1R, are mainly involved in thrombosis. The importance of these receptors for platelet aggregation and thrombus development was revealed by studies of P2Y 1 R-and P2Y 12 R-deficient mice (André et al., 2003; Koller et al., 1999; Lenain, Freund, Léon, Cazenave, & Gachet, 2003; Léon et al., 1999) . Indeed, P2Y 12 R inhibitors, such as clopidogrel, are already in clinical use as antithrombotic agents. P2Y 12 R couples with Gα i2 , leading to inhibition of adenylyl cyclase (Daniel, Dangelmaier, Jin, Kim, & Kunapuli, 1999) . It is well known that cAMP is a major regulator of platelet aggregation (Kapoor, 2008) . Adenosine acts as a platelet inhibitory mediator, and adenosine A 2A receptor-mediated cAMP production inhibits ADP-induced platelet aggregation (Fuentes et al., 2014) . P2Y 12 R-mediated inhibition of adenylyl cyclase is observed in platelets. However the reduced cAMP levels are not sufficient to induce platelet aggregation (Daniel et al., 1999; Savi, Pflieger, & Herbert, 1996) and other signaling events are involved in full activation of platelets. P2Y 12 R signaling also leads to activation of PI3K, Akt, Rap1b and K + channels through Gβγ (Gratacap et al., 2000; Kamae et al., 2006; Kim, Jin, & Kunapuli, 2003; Shankar et al., 2004; Trumel et al., 1999) , and PI3Kγ-deficient mice show impairment of ADP-induced platelet aggregation (Hirsch et al., 2001 ). In addition, G q -coupled P2Y 1 R signaling leads to platelet shape changes and aggregation through Ca 2+ mobilization (Hechler et al., 1998; Jin, Daniel, & Kunapuli, 1998; Koller et al., 1999; Léon et al., 1999) . Importantly, treatment with P2Y 1 R or P2Y 12 R antagonist alone blocks ADP-induced platelet aggregation (Eckly, Gendrault, Hechler, Cazenave, & Gachet, 2001; Jin et al., 1998) . Moreover, ADP-induced platelet aggregation is drastically impaired in both P2Y 1 R (Léon et al., 1999) and P2Y 12 R (Foster et al., 2001 ) knockout mice. Both P2Y 1 R-mediated G q and P2Y 12 R-mediated G i signaling are required for synergistic activation of platelet functions.
Platelet aggregation
The function of P2Y 12 R in platelet aggregation has been well established, in part by the clinical efficacy of P2Y 12 R antagonists as anti-platelet drugs. Several P2Y 12 R antagonists have been developed. Ticlopidine is a first-generation thienopyridine and was the first FDAapproved P2Y 12 R antagonist. However, ticlopidine use is currently discouraged because of its slow onset action and a risk of life-threatening adverse effects (Bertrand, Rupprecht, Urban, & Gershlick, 2000) . Clopidogrel is a second-generation thienopyridine, which is safer and better tolerated than ticlopidine (Bertrand et al., 2000) . Additionally, clopidogrel is more effective than aspirin in decreasing the risk of ischemic events (CAPRIE Steering Committee, 1996) . Prasugrel is a thirdgeneration thienopyridine. Thienopyridines are all prodrugs that require metabolic activation to produce an active metabolite, which irreversibly modifies and inhibits P2Y 12 R. Because prasugrel needs only one-step metabolic activation, its pharmacokinetic process is more efficient than that of clopidogrel, leading to a faster onset action (Brandt et al., 2007; Wiviott et al., 2007) . Ticagrelor is the first oral antiplatelet drug belonging to a new class called cyclopentyl-triazolo-pyrimidines. Ticagrelor reversibly and directly binds to P2Y 12 Rs without metabolic conversion, providing earlier onset of action and more consistent platelet inhibition than clopidogrel (Husted & van Giezen, 2009; van Giezen, Berntsson, Zachrisson, & Björkman, 2009) . Large clinical trials showed that ticagrelor is more effective than clopidogrel in patients with acute coronary syndrome (Andell et al., 2015; Cannon et al., 2007; Husted et al., 2005; Lindholm et al., 2014) . In addition to P2Y 12 R antagonism, ticagrelor also inhibits the equilibrative nucleotide transporter 1 (ENT1), which protects adenosine from intracellular metabolism. In fact, plasma adenosine levels are increased in patients taking ticagrelor (Armstrong et al., 2011; Bonello et al., 2014; Nylander et al., 2013; van Giezen, Sidaway, Glaves, Kirk, & Björkman, 2012) . The increased adenosine inhibits platelet aggregation via A 2A receptors, which contribute to the antiplatelet effect of ticagrelor (Cattaneo, Schulz, & Nylander, 2014; Nylander et al., 2013) .
Other ADP-sensitive P2Y 1 Rs also induce platelet aggregation. But although results from studies of P2Y 1 R knockout mice and the effects of pharmacological P2Y 1 R antagonists suggest P2Y 1 R could serve as a target of anti-platelet drugs, no P2Y 1 R antagonist is yet clinically available. MRS2500 is a selective and potent P2Y 1 R antagonist (Kim, Ohno, et al., 2003) , and Wong et al recently reported that MRS2500 prevents arterial thrombosis in a monkey model of electrolytic-mediated thrombosis (Wong, Watson, & Crain, 2016) .
Salt-resistant hypertension
Kidneys control the levels of water and electrolytes in the blood and are therefore essential for salt and fluid homeostasis, and are deeply involved in the regulation of blood pressure (Guyton, 1992) . ENaC is a major regulator of salt and water reabsorption in the kidney. Pharmacological studies indicate that ATP acts via P2Y 2 R to inhibit ENaC-mediated salt reabsorption (Deetjen, Thomas, Lehrmann, Kim, & Leipziger, 2000; Lehrmann, Thomas, Kim, Jacobi, & Leipziger, 2002; Pochynyuk et al., 2008 Pochynyuk et al., , 2010 . Phosphatidylinositol 4,5-bisphosphate (PIP 2 ) positively regulates ENaC activity (Ma, Saxena, & Warnock, 2002; Yue, Malik, Yue, & Eaton, 2002) . P2Y 2 R inhibits ENaC activity through the PLC-dependent hydrolysis of PIP 2 . Rieg et al. reported that P2Y 2 R-deficient mice exhibit salt-resistant arterial hypertension related to enhanced renal salt and water reabsorption (Rieg et al., 2007) , while agonist-induced P2Y 2 R activation reduces blood pressure by inhibiting renal salt reabsorption (Rieg, Gerasimova, Boyer, Insel, & Vallon, 2011) .
Role of P2YRs in cardiac homeostasis and disease
Cardiac contractility
Extracellular nucleotides can exert both physiological and pathophysiological effects on the heart. ATP is released from sympathetic nerves in the heart as a co-transmitter. It is also released from endothelium, platelets and the myocardium, especially if the myocardium is hypoxic (Forrester & Williams, 1977; Fredholm, Hedqvist, Lindstrom, & Wennmalm, 1982; Vial, Owen, Opie, & Posel, 1987) . The ATP concentration in the interstitial space is increased by stresses such as ischemia, mechanical stress, increased work load and cardiotonic agents (Vassort, 2001) . ATP, UDP and UTP all exert positive inotropic effects in rat atria (Froldi et al., 1994) . The inotropic effects of UDP and UTP are respectively mediated by P2Y 6 R and P2Y 2 R on cardiomyocytes (Wihlborg et al., 2006) (Table 3) . P2Y 4 R also binds UTP, but its expression level in the human heart is much lower than that of P2Y 2 R (Wihlborg et al., 2006) . The Inotropic effects of ATP are regulated via both IP3 and cAMP signaling pathways, and G s -coupled P2Y 11 R is also involved in the positive inotropic action (Balogh et al., 2005) .
Cardiac development and physiological hypertrophy
Purinergic signaling plays important roles in the development of the heart (Burnstock & Dale, 2015) . Expression of P2Y 2 R, P2Y 4 R and P2Y 6 R has been detected in the human fetal heart. In rat, expression of P2YR A P2Y 6 R antagonist reduces pressure overload-induced cardiac fibrosis. Nishida et al. (2008) P2Y 11 R ATP-induced cardiomyocyte contraction via a G s -cAMP pathway Balogh et al. (2005) MI, myocardial infarction; AT1R, angiotensin II type 1 receptor; NF-κB, nuclear factor-κB; PDGF-B, platelet-derived growth factor subunit B; ECs, endothelial cells; differs between neonatal and adult cardiomyocytes. In neonatal cardiomyocytes, P2Y 1 R is expressed to a greater degree than P2Y 2 R, P2Y 4 R or P2Y 6 R. In adult cardiomyocytes, the expression patterns of P2Y 1 R, P2Y 2 R and P2Y 6 R are the same as in neonates, but P2Y 4 R expression is no longer detectable. UTP, but not ATP, induces hypertrophic growth of neonatal cardiomyocytes, though both ligands induce ERK activation to the same extent (Pham et al., 2003) . UTP-mediated P2Y 4 R activation has different effects on contractile activity in 7-day-old and 100-day-old rat hearts (Anikina, Anisimova, & Sitdikov, 2012) . Moreover, a recent study of P2Y 4 R knockout mice shows that loss of P2Y 4 R leads to a microcardiac phenotype (Horckmans, Robaye, et al., 2012) ; that is, heart growth is diminished after birth in P2Y 4 R-null mice. P2Y 4 R is expressed in cardiac endothelial cells but not cardiomyocytes after birth, and UTP acting via endothelial P2Y 4 Rs induces cell migration, proliferation and PDGF-B secretion. This suggests P2Y 4 R-mediated endothelial-cardiomyocyte interactions are crucial for post-neonatal heart development. Exercise training induces physiological cardiac hypertrophy. P2Y 4 R-null mice show reduced exercise capacity and adaptive hypertrophy (Horckmans, Léon-Gόmez, et al., 2012) . Conversely, P2Y 6 R-deficient mice display a macrocardiac phenotype. Cardiomyocytes isolated from P2Y 6 R-null mice are more proliferative than those from wild-type mice, resulting in postnatal hypergrowth of the heart (Clouet et al., 2016) . These results suggest that purinergic P2YR signaling is involved in the physiological development of the heart.
Heart failure
Prolonged severe stress, such as myocardial infarction and pressureoverload, induces pathological cardiac remodeling, including fibrosis, cell death and senescence. Such pathological remodeling leads to cardiac dysfunction and subsequent heart failure. ATP and UTP are released from cardiomyocytes and cardiac fibroblasts during cardiac ischemia (Clarke, Williams, Martin, & Evans, 2009; Dolmatova et al., 2012; Erlinge et al., 2005; Lu, Soleymani, Madakshire, & Insel, 2012; Sesti, Koyama, Broekman, Marcus, & Levi, 2003) . In addition, we and other groups have shown that cardiac P2Y 2 R and P2Y 6 R expression is upregulated during chronic heart failure and dystrophic cardiomyopathy in mice (De Oliveira Moreira, Santo Neto, & Marques, 2017; Hou et al., 1999; Nishida et al., 2008) .
UTP treatment has cardioprotective effects in vitro and in vivo and improves cardiac function in heart failure-model animals (Shainberg, Yitzhaki, Golan, Jacobson, & Hochhauser, 2009; Wee, Peart, & Headrick, 2007; Yitzhaki, Shneyvays, Jacobson, & Shainberg, 2005; Yitzhaki et al., 2006) . Pharmacological studies using a P2Y 2 R-selective agonist and studies with P2Y 2 R knockout mice showed that P2Y 2 R signaling protects the heart from ischemic damage (Cohen et al., 2011; Hochhauser et al., 2013) . We previously reported that P2Y 2 R signaling down-regulates AT1R density in pressure-overloaded hearts (Nishida et al., 2011) .
Ang II plays a crucial role in cardiovascular homeostasis, and its dysregulation leads to various cardiovascular diseases (de Gasparo, Catt, Inagami, Wright, & Unger, 2000) . Although Ang II acts via two GPCRs, AT1R and AT2R, AT1R accounts for most cardiovascular effects of Ang II. The pathophysiological relevance of aberrant AT1R expression has been observed in cultured cells and animals, and in clinical interventional trials (Wassmann & Nickenig, 2006) . ATP-induced P2Y 2 R activation reduces AT1R density through the calcineurin-nuclear factor of activated T cell (NFAT) signaling pathway. NFAT stimulates inducible NO synthase (iNOS) expression, and NO-mediated S-nitrosylation of the p65 subunit of NF-κB decreases its transcriptional activity and AT1R density. In fact, AT1R expression is reduced in the pressureoverloaded heart, and suramin, a P2YR inhibitor, reverses that downregulation (Nishida et al., 2011) .
Increased sympathetic activity is associated with cardiac hypertrophy, and isoproterenol-induced cardiac hypertrophy is enhanced in P2Y 6 R-null mice (Clouet et al., 2016) . We previously described the role of P2Y 6 R signaling during pressure overload (Nishida et al., 2008) . P2Y 6 R is upregulated in the pressure-overloaded heart, and its activation in cardiomyocytes induces expression of fibrogenic genes through a Gα 12/13 -RhoA signaling axis, leading to cardiac fibrosis (Fig. 4) . Mechanical stretching of cardiomyocytes leads to ATP and UDP release through pannexin-1. In transgenic mice overexpressing a dominant a negative form of p115RhoGEF, which acts as a Gα 12/13 inhibitor, the resultant pharmacological inhibition of P2Y 6 R diminishes pressure overload-induced cardiac dysfunction and fibrosis, but not hypertrophy. Other uridine nucleotide-responsive P2Y 4 Rs are also involved in pathological heart remodeling (Horckmans et al., 2015) . P2Y 4 R-null mice are protected during myocardial infarction by reductions in microvascular hyperpermeability and neutrophil infiltration. Additionally, the Ala-87-Thr polymorphism of P2Y 11 R is reportedly associated with an increased risk of acute myocardial infarction (Amisten, Melander, Wihlborg, Berglund, & Erlinge, 2006) . 5. P2Y 6 R as a risk factor for cardiovascular diseases
Age-related hypertension
Because of increasing life expectancy, it is estimated that the population of people over age 69 may increase from 11% to 22% by the year 2050 (Roberts, 2011; Silva-Palacios, Königsberg, & Zazueta, 2016) . Aging is considered a major non-modifiable risk factor for the development of cardiovascular diseases, including hypertension (Wang, Monticone, & Lakatta, 2010) . In fact, aortic morphology dramatically changes with aging (Virmani et al., 1991) . Increases in arterial stiffness (Harvey, Montezano, Lopes, Rios, & Touyz, 2016; Kass, 2005) and vascular tone (Wirth et al., 2016) , and endothelial dysfunction (Camici, Sudano, Noll, Tanner, & Lüscher, 2009; Toda, 2012; Vanhoutte, Shimokawa, Feletou, & Tang, 2017) are key factors contributing to age-dependent hypertension.
The renin-angiotensin-aldosterone system (RAAS) and its primary active product, Ang II, plays a central role in cardiovascular homeostasis, but is also a critical contributor to the development of hypertension (Daugherty & Cassis, 2004) . Ang II promotes vascular smooth muscle cell hypertrophy, leading to pathological arterial remodeling and hypertension (Heeneman, Sluimer, & Daemen, 2007) . Notably, the responsiveness of arteries to Ang II is age-dependent (Cai, Gurdal, Seasholtz, & Johnson, 1994; Vamos et al., 2014) . Whereas Ang II induces physiological proliferation of neonatal vascular smooth muscle cells, it leads to pathological hypertrophy of adult vascular smooth muscle cells (Deguchi, Makuuchi, Nakaoka, Collins, & Takuwa, 1999) . We previously showed that P2Y 6 R is involved in age-related changes in Ang II responsiveness (Nishimura et al., 2016) . Expression of P2Y 6 R but not AT1R is developmentally increased in vascular smooth muscle cells (Fig. 4) . Ang II-stimulated AT1R activates two signaling pathways: G proteinmediated hypertrophic signaling and β-Arr-mediated proliferative signaling. Interestingly, P2Y 6 R forms a heterodimer with AT1R, which disrupts Ang II-triggered β-Arr recruitment to AT1R and potentiates G protein-dependent hypertrophic signaling. While neonatal vascular smooth muscle cells only weakly express P2Y 6 R and show proliferative responses to Ang II, adult cells strongly express P2Y 6 R and show hypertrophic responses to Ang II. In addition, overexpression or knockdown of P2Y 6 R alters the Ang II responsiveness of these cells. These results suggest that age-dependent increases in P2Y 6 R expression determines pathological vascular effects of Ang II and increases cardiovascular risk. In fact, P2Y 6 R-deficient mice exhibit less Ang II-induced pathological arterial remodeling in response to hypertension than wild-type mice.
In addition to aging, P2Y 6 R expression is also up-regulated by environmental stresses such as pressure-overload and activation of Gα 13 -mediated signaling (Nishida et al., 2008) and inflammation (Riegel et al., 2011) , though the regulation mechanism of its gene expression is still unclear. It also has been reported age-dependent changes in expression of other P2YRs (Burnstock & Dale, 2015; Sunggip et al., 2017) . For instance, P2Y 1 R and P2Y 2 R mRNA are up-regulated in smooth muscle cells and down-regulated in endothelial cells with age (Miao, Tang, Esposito, & Zhang, 2001 Fig. 6 . Pharmacological disruption of AT1R-P2Y 6 R heterodimerization alters AT1R-mediated pathological signaling. P2Y 6 R forms a heterodimer with AT1R. After AT1R is activated by Ang II or mechanical stress, this heterodimer inhibits β-arrestin (βArr) recruitment to AT1Rs and the resultant receptor desensitization, leading to hyperactivation of G protein-dependent hypertrophic signaling and hypertension. MRS2578 (MRS) disrupts AT1R-P2Y 6 R heterodimerization, and βArr can be recruited to AT1R after activation. 
Regulation of cardiac risk
Metabolic disease
Obesity is a serious public health issue worldwide; nearly one-third of the world's population is obese or overweight (Finucane et al., 2011) . Obesity is associated with an increased risk of mortality and morbidity from cardiovascular disease. Control of food intake is important for maintenance of energy balance, and obese and overweight persons often claim that their eating is out of control. Multiple neuron populations in the central nervous system control food intake (Morton, Cummings, Baskin, Barsh, & Schwartz, 2006) . Activation of orexigenic agouti-related peptide (AgRP)-expressing neurons in the arcuate nucleus of the hypothalamus potently enhances feeding (Ollmann et al., 1997) . Steculorum et al. reported that AgRP neurons express P2Y 6 R, and an increase in hypothalamic UDP levels in obesity promotes feeding through P2Y 6 R-dependent activation of AgRP neurons (Steculorum et al., 2015) . Hypothalamic UDP synthesis is increased in obesity as a result of an elevated circulating uridine supply. Moreover, AgRP neuronspecific inactivation of P2Y 6 R reduces food intake and improves systemic insulin sensitivity in obesity (Steculorum et al., 2017) .
Impaired glucose homeostasis and insulin secretion are associated with diabetes mellitus, which is a major risk factor for cardiovascular disease. Glucose uptake into peripheral tissues, including skeletal muscles and adipocytes, is essential for the maintenance of glucose homeostasis. In mouse C2C12 myotubes and 3T3-L1 adipocytes, a P2Y 6 R agonist, P 1 -(5′-uridine)-P 3 -(5′-N 4 -methoxycytidine)-triphosphate (MRS2957), increased glucose uptake and recruitment of facilitated glucose transporter-4 (GLUT4) through activation of 5′-AMP-activated protein kinase (AMPK), while, N,N″-1,4-butanediyl-bis[N′-(3-isothiocyanatophenyl)thiourea] (MRS2578), a P2Y 6 R antagonist, significantly reduced these responses (Balasubramanian, Robaye, Boeynaems, & Jacobson, 2014) . Treating primary mouse adipocytes from wild-type mice with MRS2957 or UDP also stimulates glucose uptake, whereas these agonists have no impact on glucose uptake into adipocytes from P2Y 6 R-knockout mice. P2Y 6 R thus appears to promote glucose metabolism through activation of AMPK signaling in peripheral tissues. P2Y 6 R also reportedly participates in the potentiation of insulin secretion from pancreatic β cells (Sassmann et al., 2010) . Sassman et al. found that β cell-specific inactivation of Gα q /Gα 11 results in impaired glucose tolerance and insulin secretion in mice. Gα q /Gα 11 -deficient β cells show a loss of muscarinic or metabolic potentiation of insulin release and glucose-induced membrane depolarization due to closure of K ATP channels. This reduced excitability was due to co-secreted UDP and Ca 2+ , both of which activate Gα q /Gα 11 -mediated signaling via P2Y 6 R and Ca 2+ -sensing receptor.
Electrolyte homeostasis
Proper electrolyte balance is essential for maintaining good cardiac function, and electrolyte imbalances increase the risk of cardiac arrhythmias. Electrolyte transport in the mammalian colon includes both absorptive and secretory processes. NaCl is either absorbed electroneutrally via parallel apical Cl − /HCO3 − and Na + /H + antiporters or electrogenically via apical ENaC channels located in the distal colon (Kunzelmann & Mall, 2002) . Basolateral P2Y 6 Rs on colonic epithelial cells mediate sustained NaCl secretion by way of a synergistic increases in the intracellular Ca 2+ and cAMP levels (Köttgen et al., 2003) .
Basolateral UDP activates cAMP-stimulated basolateral KCNQ1/KCNE3 K + channels, which leads to sustained activation of Cl − secretion.
6. Conclusion: therapeutic strategy targeting P2Y 6 Rs for cardiovascular diseases
As described above, P2YRs play important roles in cardiovascular homeostasis and diseases. P2Y 6 R, in particular, is ubiquitously expressed in many organs and tissues, where it is involved in glucose homeostasis, insulin resistance, obesity, hypertension, and electrolyte homeostasis (Fig. 5) . P2Y 6 R is upregulated with aging and under pathological conditions such as arterial inflammation and hemodynamic overload of the heart, and it contributes to the pathogenesis of cardiovascular remodeling in mice. Allosteric modulation of P2Y 6 R by MRS2578, a P2Y 6 R antagonist, suppresses heterodimer formation by P2Y 6 R with AT1R, which reduces the risk for Ang II-induced hypertension (Fig. 6) . Interestingly, even in the absence of a ligand, AT1Rs on cardiomyocytes are reportedly activated by mechanical stretch, and contribute to pressure overloadinduced cardiac hypertrophy in mice (Zou et al., 2004) . P2Y 6 R might also contribute to mechanical stress-induced cardiovascular remodeling through interaction with AT1Rs. We anticipate that targeting inhibition of P2Y 6 R heterodimerization will offer a new therapeutic strategy for the prevention and treatment of cardiovascular diseases.
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